Oklahoma 2023 Regular Session

Oklahoma Senate Bill SB452 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB452 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	1st Session of the 59th Legislature (2023)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 452 By: Standridge of the Senate
7	37
8	38		and
9	39
10	40		Marti of the House
11	41
12	42
13	43
14	44
15	45		An Act relating to the Uniform Controlled Dangerous
16	46		Substances Act; amending 63 O.S. 2021, Section 2-204,
17	47		as amended by Section 1, Ch apter 70, O.S.L. 2022 (63
18	48		O.S. Supp. 2022, Section 2 -204), which relates to
19	49		Schedule I; including certain chemicals in the list
20	50		of Schedule I substances ; and providing an effective
21	51		date.
22	52
23	53
24	54
25	55
26	56
27		-	SUBJECT: Uniform Controlled Dangerou s Substances Act
28		-
29	57		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
30		-
31	58		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -204, as
32	59		amended by Section 1, Chapter 70, O.S.L. 2022 (63 O.S. Supp. 2022,
33	60		Section 2-204), is amended to read as follow s:
34		-
35	61		Section 2-204. The controlled substances listed in this section
36	62		are included in Schedule I and include any material, compound,
37	63		mixture or preparation that contains any quan tity of the following
38	64		hallucinogenic substances, their salts, isomers and salts of
39	65		isomers, unless specifically excepted, when the existence of these
	66	+
	67	+	SB452 HFLR Page 2
	68	+	BOLD FACE denotes Committee Amendments. 1
	69	+	2
	70	+	3
	71	+	4
	72	+	5
	73	+	6
	74	+	7
	75	+	8
	76	+	9
	77	+	10
	78	+	11
	79	+	12
	80	+	13
	81	+	14
	82	+	15
	83	+	16
	84	+	17
	85	+	18
	86	+	19
	87	+	20
	88	+	21
	89	+	22
	90	+	23
	91	+	24
	92	+
40	93		salts, isomers and salts of isomers is possible within the specific
41	94		chemical designation.
42		-
43	95		A. Any of the following opiates including their isomers,
44	96		esters, ethers, salts, and salts of isomers, esters, and ethers,
45	97		unless specifically excepted, when the existence of these isomers,
46		-
47		-	ENR. S. B. NO. 452 Page 2
48	98		esters, ethers, and salts is possible within the specific chemical
49	99		designation:
50		-
51	100		1. Acetylmethadol;
52		-
53	101		2. Allylprodine;
54		-
55	102		3. Alphacetylmethadol;
56		-
57	103		4. Alphameprodine;
58		-
59	104		5. Alphamethadol;
60		-
61	105		6. Benzethidine;
62		-
63	106		7. Betacetylmethadol;
64		-
65	107		8. Betameprodine;
66		-
67	108		9. Betamethadol;
68		-
69	109		10. Betaprodine;
70		-
71	110		11. Clonitazene;
72		-
73	111		12. Dextromoramide;
74		-
75	112		13. Dextrorphan (except its methyl ether);
76		-
77	113		14. Diampromide;
78		-
79	114		15. Diethylthiambutene;
80		-
81	115		16. Dimenoxadol;
82		-
83	116		17. Dimepheptanol;
84	117
	118	+	SB452 HFLR Page 3
	119	+	BOLD FACE denotes Committee Amendments. 1
	120	+	2
	121	+	3
	122	+	4
	123	+	5
	124	+	6
	125	+	7
	126	+	8
	127	+	9
	128	+	10
	129	+	11
	130	+	12
	131	+	13
	132	+	14
	133	+	15
	134	+	16
	135	+	17
	136	+	18
	137	+	19
	138	+	20
	139	+	21
	140	+	22
	141	+	23
	142	+	24
	143	+
85	144		18. Dimethylthiambutene;
86		-
87	145		19. Dioxaphetyl butyrate;
88		-
89	146		20. Dipipanone;
90		-
91		-	ENR. S. B. NO. 452 Page 3
92		-
93	147		21. Ethylmethylthiambutene;
94		-
95	148		22. Etonitazene;
96		-
97	149		23. Etoxeridine;
98		-
99	150		24. Furethidine;
100		-
101	151		25. Hydroxypethidine;
102		-
103	152		26. Isotonitazene;
104		-
105	153		26. 27. Ketobemidone;
106		-
107	154		27. 28. Levomoramide;
108		-
109	155		28. 29. Levophenacylmorphan;
110		-
111	156		29. 30. Metonitazene;
112		-
113	157		30. 31. Morpheridine;
114		-
115	158		32. N-desethyl isotonitazene;
116		-
117	159		31. 33. Noracymethadol;
118		-
119	160		32. 34. Norlevorphanol;
120		-
121	161		33. 35. Normethadone;
122		-
123	162		34. 36. Norpipanone;
124		-
125	163		35. 37. Phenadoxone;
126		-
127	164		36. 38. Phenampromide;
128		-
129	165		37. 39. Phenomorphan;
130		-
131	166		38. 40. Phenoperidine;
132		-
133	167		39. 41. Piritramide;
134	168
135		-	ENR. S. B. NO. 452 Page 4
	169	+	SB452 HFLR Page 4
	170	+	BOLD FACE denotes Committee Amendments. 1
	171	+	2
	172	+	3
	173	+	4
	174	+	5
	175	+	6
	176	+	7
	177	+	8
	178	+	9
	179	+	10
	180	+	11
	181	+	12
	182	+	13
	183	+	14
	184	+	15
	185	+	16
	186	+	17
	187	+	18
	188	+	19
	189	+	20
	190	+	21
	191	+	22
	192	+	23
	193	+	24
136	194
137	195		40. 42. Proheptazine;
138		-
139	196		41. 43. Properidine;
140		-
141	197		44. Protonitazene;
142		-
143	198		42. 45. Racemoramide; or
144		-
145	199		43. 46. Trimeperidine.
146		-
147	200		B. Any of the following opium derivatives, their salts,
148	201		isomers, and salts of isomers, unless specifi cally excepted, when
149	202		the existence of these salts, isomers, and salts of isomers is
150	203		possible within the specific chemical designation:
151		-
152	204		1. Acetorphine;
153		-
154	205		2. Acetyldihydrocodeine;
155		-
156	206		3. Benzylmorphine;
157		-
158	207		4. Codeine methylbromide;
159		-
160	208		5. Codeine-N-Oxide;
161		-
162	209		6. Cyprenorphine;
163		-
164	210		7. Desomorphine;
165		-
166	211		8. Dihydromorphine;
167		-
168	212		9. Etorphine;
169		-
170	213		10. Heroin;
171		-
172	214		11. Hydromorphinol;
173		-
174	215		12. Methyldesorphine;
175		-
176	216		13. Methylhydromorphine;
177		-
178		-
179		-	ENR. S. B. NO. 452 Page 5
180	217		14. Morphine methylbromide;
181		-
182	218		15. Morphine methylsulfonate;
183	219
	220	+	SB452 HFLR Page 5
	221	+	BOLD FACE denotes Committee Amendments. 1
	222	+	2
	223	+	3
	224	+	4
	225	+	5
	226	+	6
	227	+	7
	228	+	8
	229	+	9
	230	+	10
	231	+	11
	232	+	12
	233	+	13
	234	+	14
	235	+	15
	236	+	16
	237	+	17
	238	+	18
	239	+	19
	240	+	20
	241	+	21
	242	+	22
	243	+	23
	244	+	24
	245	+
184	246		16. Morphine-N-Oxide;
185		-
186	247		17. Myrophine;
187		-
188	248		18. Nicocodeine;
189		-
190	249		19. Nicomorphine;
191		-
192	250		20. Normorphine;
193		-
194	251		21. Phoclodine;
195		-
196	252		22. Thebacon;
197		-
198	253		23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
199	254		(Acetyl fentanyl);
200		-
201	255		24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
202	256		(Crotonyl fentanyl);
203		-
204	257		25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
205	258		furancarboxamide (Furanyl fentanyl);
206		-
207	259		26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
208		-
209	260		27. N-(1-phenethylpiperidin-4-yl)-N-
210	261		phenylcyclopropanecarboxamide (Cyclopropyl fen tanyl); or
211		-
212	262		28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
213	263		(Butyrl fentanyl).
214		-
215	264		C. Any material, compound, mixture, or preparation wh ich
216	265		contains any quantity of the following hallucinogenic substances,
217	266		their salts, isomers, and salts of isomer s, unless specifically
218	267		excepted, when the ex istence of these salts, isomers, and salts of
219	268		isomers is possible within the specific chemical design ation:
220		-
221	269		1. Methcathinone;
222	270
223		-	ENR. S. B. NO. 452 Page 6
	271	+	SB452 HFLR Page 6
	272	+	BOLD FACE denotes Committee Amendments. 1
	273	+	2
	274	+	3
	275	+	4
	276	+	5
	277	+	6
	278	+	7
	279	+	8
	280	+	9
	281	+	10
	282	+	11
	283	+	12
	284	+	13
	285	+	14
	286	+	15
	287	+	16
	288	+	17
	289	+	18
	290	+	19
	291	+	20
	292	+	21
	293	+	22
	294	+	23
	295	+	24
224	296
225	297		2. 3, 4-methylenedioxy amphetamine;
	298	+	3. 3, 4-methylenedioxy methamphetamine;
	299	+	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
	300	+	5. 3, 4, 5-trimethoxy amphetamine;
	301	+	6. Bufotenine;
	302	+	7. Diethyltryptamine;
	303	+	8. Dimethyltryptamine;
	304	+	9. 4-methyl-2, 5-dimethoxyamphetamine;
	305	+	10. Ibogaine;
	306	+	11. Lysergic acid diethylamide;
	307	+	12. Marijuana;
	308	+	13. Mescaline;
	309	+	14. N-benzylpiperazine;
	310	+	15. N-ethyl-3-piperidyl benzilate;
	311	+	16. N-methyl-3-piperidyl benzilate;
	312	+	17. Psilocybin;
	313	+	18. Psilocyn;
	314	+	19. 2, 5 dimethoxyamphetamine;
	315	+	20. 4 Bromo-2, 5-dimethoxyamphetamine;
	316	+	21. 4 methoxyamphetamine;
	317	+	22. Cyclohexamine;
	318	+	23. Salvia Divinorum;
	319	+	24. Salvinorin A;
226	320
227		-	3. 3, 4-methylenedioxy metham phetamine;
228		-
229		-	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
230		-
231		-	5. 3, 4, 5-trimethoxy amphetamine;
232		-
233		-	6. Bufotenine;
234		-
235		-	7. Diethyltryptamine;
236		-
237		-	8. Dimethyltryptamine;
238		-
239		-	9. 4-methyl-2, 5-dimethoxyamphetamine;
240		-
241		-	10. Ibogaine;
242		-
243		-	11. Lysergic acid diethylamide;
244		-
245		-	12. Marijuana;
246		-
247		-	13. Mescaline;
248		-
249		-	14. N-benzylpiperazine;
250		-
251		-	15. N-ethyl-3-piperidyl benzilate;
252		-
253		-	16. N-methyl-3-piperidyl benzilate;
254		-
255		-	17. Psilocybin;
256		-
257		-	18. Psilocyn;
258		-
259		-	19. 2, 5 dimethoxyamphetamine;
260		-
261		-	20. 4 Bromo-2, 5-dimethoxyamphetamine;
262		-
263		-	21. 4 methoxyamphetamine;
264		-
265		-	22. Cyclohexamine;
266		-
267		-	ENR. S. B. NO. 452 Page 7
268		-
269		-	23. Salvia Divinorum;
270		-
271		-	24. Salvinorin A;
	321	+	SB452 HFLR Page 7
	322	+	BOLD FACE denotes Committee Amendments. 1
	323	+	2
	324	+	3
	325	+	4
	326	+	5
	327	+	6
	328	+	7
	329	+	8
	330	+	9
	331	+	10
	332	+	11
	333	+	12
	334	+	13
	335	+	14
	336	+	15
	337	+	16
	338	+	17
	339	+	18
	340	+	19
	341	+	20
	342	+	21
	343	+	22
	344	+	23
	345	+	24
272	346
273	347		25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
274	348		thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
275	349		TPCP, TCP;
276		-
277	350		26. Phencyclidine (PCP);
278		-
279	351		27. Pyrrolidine Analog for Phencyclidine . Also known as 1-(1-
280	352		Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
281		-
282	353		28. 1-(3-trifluoromethylphenyl) piperazine;
283		-
284	354		29. Flunitrazepam;
285		-
286	355		30. B-hydroxy-amphetamine;
287		-
288	356		31. B-ketoamphetamine;
289		-
290	357		32. 2,5-dimethoxy-4-nitroamphetamine;
291		-
292	358		33. 2,5-dimethoxy-4-bromophenethylamine;
293		-
294	359		34. 2,5-dimethoxy-4-chlorophenethylamine;
295		-
296	360		35. 2,5-dimethoxy-4-iodoamphetamine;
297		-
298	361		36. 2,5-dimethoxy-4-iodophenethylamine;
299		-
300	362		37. 2,5-dimethoxy-4-methylphenethylamine;
301		-
302	363		38. 2,5-dimethoxy-4-ethylphenethylamine;
303		-
304	364		39. 2,5-dimethoxy-4-fluorophenethylamine;
305		-
306	365		40. 2,5-dimethoxy-4-nitrophenethylamine;
307		-
308	366		41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
309		-
310		-
311		-	ENR. S. B. NO. 452 Page 8
312	367		42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
313		-
314	368		43. 2,5-dimethoxy-4-propylthio-phenethylamine;
315		-
316	369		44. 2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine;
317		-
318	370		45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
319	371
	372	+	SB452 HFLR Page 8
	373	+	BOLD FACE denotes Committee Amendments. 1
	374	+	2
	375	+	3
	376	+	4
	377	+	5
	378	+	6
	379	+	7
	380	+	8
	381	+	9
	382	+	10
	383	+	11
	384	+	12
	385	+	13
	386	+	14
	387	+	15
	388	+	16
	389	+	17
	390	+	18
	391	+	19
	392	+	20
	393	+	21
	394	+	22
	395	+	23
	396	+	24
	397	+
320	398		46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
321		-
322	399		47. 5-methoxy-N, N-dimethyltryptamine;
323		-
324	400		48. N-methyltryptamine;
325		-
326	401		49. A-ethyltryptamine;
327		-
328	402		50. A-methyltryptamine;
329		-
330	403		51. N, N-diethyltryptamine;
331		-
332	404		52. N, N-diisopropyltryptamine;
333		-
334	405		53. N, N-dipropyltryptamine;
335		-
336	406		54. 5-methoxy-a-methyltryptamine;
337		-
338	407		55. 4-hydroxy-N, N-diethyltryptamine;
339		-
340	408		56. 4-hydroxy-N, N-diisopropyltryptamine;
341		-
342	409		57. 5-methoxy-N, N-diisopropyltryptamine;
343		-
344	410		58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
345		-
346	411		59. 3,4-Methylenedioxymethcathinone (Methylone);
347		-
348	412		60. 3,4-Methylenedioxypyrovalerone (MDPV);
349		-
350	413		61. 4-Methylmethcathinone (Mephedrone);
351		-
352	414		62. 4-methoxymethcathinone;
353		-
354		-
355		-	ENR. S. B. NO. 452 Page 9
356	415		63. 4-Fluoromethcathinone;
357		-
358	416		64. 3-Fluoromethcathinone;
359		-
360	417		65. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
361		-
362	418		66. 2,5-Dimethoxy-4-chloroamphetamine;
363		-
364	419		67. 4-Methylethcathinone;
365		-
366	420		68. Pyrovalerone;
367		-
368	421		69. N,N-diallyl-5-methoxytryptamine;
369	422
	423	+	SB452 HFLR Page 9
	424	+	BOLD FACE denotes Committee Amendments. 1
	425	+	2
	426	+	3
	427	+	4
	428	+	5
	429	+	6
	430	+	7
	431	+	8
	432	+	9
	433	+	10
	434	+	11
	435	+	12
	436	+	13
	437	+	14
	438	+	15
	439	+	16
	440	+	17
	441	+	18
	442	+	19
	443	+	20
	444	+	21
	445	+	22
	446	+	23
	447	+	24
	448	+
370	449		70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
371		-
372	450		71. B-keto-N-Methylbenzodioxolylbutanamine (Butylon e);
373		-
374	451		72. B-keto-Methylbenzodioxolylpentanamine ( Pentylone);
375		-
376	452		73. Alpha-Pyrrolidinopentiophenone;
377		-
378	453		74. 4-Fluoroamphetamine;
379		-
380	454		75. Pentedrone;
381		-
382	455		76. 4’-Methyl-a-pyrrolidinohexaphenone;
383		-
384	456		77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
385		-
386	457		78. 2,5-dimethoxyphenethylamine;
387		-
388	458		79. 1,4-Dibenzylpiperazine;
389		-
390	459		80. N,N-Dimethylamphetamine;
391		-
392	460		81. 4-Fluoromethamphetamine;
393		-
394	461		82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)pheneth ylamine
395	462		(25C-NBOMe);
396		-
397		-
398		-	ENR. S. B. NO. 452 Page 10
399	463		83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
400	464		(25I-NBOMe);
401		-
402	465		84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
403	466		(25B-NBOMe);
404		-
405	467		85. 1-(4-Fluorophenyl)piperazine;
406		-
407	468		86. Methoxetamine;
408		-
409	469		87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
410	470		methylbenzamide;
411		-
412	471		88. N-ethyl hexadrone;
413		-
414	472		89. Isopropyl-U-47700;
415	473
	474	+	SB452 HFLR Page 10
	475	+	BOLD FACE denotes Committee Amendments. 1
	476	+	2
	477	+	3
	478	+	4
	479	+	5
	480	+	6
	481	+	7
	482	+	8
	483	+	9
	484	+	10
	485	+	11
	486	+	12
	487	+	13
	488	+	14
	489	+	15
	490	+	16
	491	+	17
	492	+	18
	493	+	19
	494	+	20
	495	+	21
	496	+	22
	497	+	23
	498	+	24
	499	+
416	500		90. Para-fluorobutyrl fentanyl;
417		-
418	501		91. Fluoro isobutryrl fentanyl;
419		-
420	502		92. 3-Hydroxy Phencyclidine (PCP);
421		-
422	503		93. 3-methoxy Phencyclidine (PCP);
423		-
424	504		94. Flualprazolam; or
425		-
426	505		95. Flubromazolam.
427		-
428	506		D. Unless specifically excepted or unless listed in a di fferent
429	507		schedule, any material, compound, mixtur e, or preparation which
430	508		contains any quantit y of the following substances having stimulant
431	509		or depressant effect on the central nervous system:
432		-
433	510		1. Fenethylline;
434		-
435	511		2. Mecloqualone;
436		-
437	512		3. N-ethylamphetamine;
438		-
439	513		4. Methaqualone;
440		-
441		-
442		-	ENR. S. B. NO. 452 Page 11
443	514		5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
444	515		hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
445	516		oxybate, and sodium oxybutyrate;
446		-
447	517		6. Gamma-Butyrolactone (GBL) as packaged, marketed,
448	518		manufactured or promoted for human consumption, with the exception
449	519		of legitimate food additive and manufacturing purposes;
450		-
451	520		7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
452	521		manufactured for human consumption, with th e exception of legitimate
453	522		food additive and manufacturing purposes ;
454	523
	524	+	SB452 HFLR Page 11
	525	+	BOLD FACE denotes Committee Amendments. 1
	526	+	2
	527	+	3
	528	+	4
	529	+	5
	530	+	6
	531	+	7
	532	+	8
	533	+	9
	534	+	10
	535	+	11
	536	+	12
	537	+	13
	538	+	14
	539	+	15
	540	+	16
	541	+	17
	542	+	18
	543	+	19
	544	+	20
	545	+	21
	546	+	22
	547	+	23
	548	+	24
	549	+
455	550		8. Gamma Valerolactone (GVL) as packaged, mar keted, or
456	551		manufactured for human consumption , with the exception of legitimate
457	552		food additive and manufacturing purposes;
458		-
459	553		9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
460	554		manufactured, or promoted for human consumption with the exception
461	555		of legitimate manufacturing purposes; or
462		-
463	556		10. N-ethylpentylone.
464		-
465	557		E. 1. The following industrial uses of Gamma-Butyrolactone,
466	558		Gamma Hydroxyvalerate, Gam ma Valerolactone, or 1,4 Butanediol are
467	559		excluded from all schedule s of controlled substances under this
468	560		title:
469		-
470	561		a. pesticides,
471		-
472	562		b. photochemical etching,
473		-
474	563		c. electrolytes of small batteries or capacitors,
475		-
476	564		d. viscosity modifiers in polyurethane,
477		-
478	565		e. surface etching of metal coated plastics,
479		-
480	566		f. organic paint disbursements for water soluble inks,
481		-
482	567		g. pH regulators in the dyeing of wool and polyamide
483	568		fibers,
484		-
485		-
486		-	ENR. S. B. NO. 452 Page 12
487	569		h. foundry chemistry as a catalyst during curing,
488		-
489	570		i. curing agents in many coating systems based on
490	571		urethanes and amides,
491		-
492	572		j. additives and flavoring agents in food, confection ary,
493	573		and beverage products,
494	574
	575	+	SB452 HFLR Page 12
	576	+	BOLD FACE denotes Committee Amendments. 1
	577	+	2
	578	+	3
	579	+	4
	580	+	5
	581	+	6
	582	+	7
	583	+	8
	584	+	9
	585	+	10
	586	+	11
	587	+	12
	588	+	13
	589	+	14
	590	+	15
	591	+	16
	592	+	17
	593	+	18
	594	+	19
	595	+	20
	596	+	21
	597	+	22
	598	+	23
	599	+	24
	600	+
495	601		k. synthetic fiber and clothing production,
496		-
497	602		l. tetrahydrofuran production,
498		-
499	603		m. gamma butyrolactone production,
500		-
501	604		n. polybutylene terephthalate resin production,
502		-
503	605		o. polyester raw materials for polyurethane elastomers
504	606		and foams,
505		-
506	607		p. coating resin raw materi al, and
507		-
508	608		q. as an intermediate in the manufacture of other
509	609		chemicals and pharmaceuticals.
510		-
511	610		2. At the request of any person, the Director may exempt any
512	611		other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
513	612		Gamma Valerolactone, or 1,4 Butanedi ol from being included as a
514	613		Schedule I controlled substance if such p roduct is labeled,
515	614		marketed, manufactured and distributed for legitimate industrial use
516	615		in a manner that reduces or eliminates the likelihood of abuse.
517		-
518	616		3. In making a determination regar ding an industrial product,
519	617		the Director, after notice and hearing, s hall consider the
520	618		following:
521		-
522	619		a. the history and current pattern of abuse,
523		-
524	620		b. the name and labeling of the product,
525		-
526	621		c. the intended manner of distribution, adve rtising and
527	622		promotion of the product, and
528		-
529		-
530		-	ENR. S. B. NO. 452 Page 13
531	623		d. other factors as may be relevant to and consistent
532	624		with the public health and safety.
533	625
	626	+	SB452 HFLR Page 13
	627	+	BOLD FACE denotes Committee Amendments. 1
	628	+	2
	629	+	3
	630	+	4
	631	+	5
	632	+	6
	633	+	7
	634	+	8
	635	+	9
	636	+	10
	637	+	11
	638	+	12
	639	+	13
	640	+	14
	641	+	15
	642	+	16
	643	+	17
	644	+	18
	645	+	19
	646	+	20
	647	+	21
	648	+	22
	649	+	23
	650	+	24
	651	+
534	652		4. The hearing shall be held in accordance with the procedures
535	653		of the Administrative Procedures Act.
536		-
537	654		F. Any material, compound, mixture, or preparation , whether
538	655		produced directly or indirectly from a substance of vegetab le origin
539	656		or independently by means of chemical synthesis, or by a combination
540	657		of extraction and chemical synthesis, that contains any quantity of
541	658		the following substances, or that contai ns any of their salts,
542	659		isomers, and salts of isomers when the existen ce of these salts,
543	660		isomers, and salts of isomers is possible within the specific
544	661		chemical designation:
545		-
546	662		1. JWH-004;
547		-
548	663		2. JWH-007;
549		-
550	664		3. JWH-009;
551		-
552	665		4. JWH-015;
553		-
554	666		5. JWH-016;
555		-
556	667		6. JWH-018;
557		-
558	668		7. JWH-019;
559		-
560	669		8. JWH-020;
561		-
562	670		9. JWH-030;
563		-
564	671		10. JWH-046;
565		-
566	672		11. JWH-047;
567		-
568	673		12. JWH-048;
569		-
570	674		13. JWH-049;
571		-
572	675		14. JWH-050;
573	676
574		-	ENR. S. B. NO. 452 Page 14
	677	+	SB452 HFLR Page 14
	678	+	BOLD FACE denotes Committee Amendments. 1
	679	+	2
	680	+	3
	681	+	4
	682	+	5
	683	+	6
	684	+	7
	685	+	8
	686	+	9
	687	+	10
	688	+	11
	689	+	12
	690	+	13
	691	+	14
	692	+	15
	693	+	16
	694	+	17
	695	+	18
	696	+	19
	697	+	20
	698	+	21
	699	+	22
	700	+	23
	701	+	24
575	702
576	703		15. JWH-070;
577		-
578	704		16. JWH-071;
579		-
580	705		17. JWH-072;
581		-
582	706		18. JWH-073;
583		-
584	707		19. JWH-076;
585		-
586	708		20. JWH-079;
587		-
588	709		21. JWH-080;
589		-
590	710		22. JWH-081;
591		-
592	711		23. JWH-082;
593		-
594	712		24. JWH-094;
595		-
596	713		25. JWH-096;
597		-
598	714		26. JWH-098;
599		-
600	715		27. JWH-116;
601		-
602	716		28. JWH-120;
603		-
604	717		29. JWH-122;
605		-
606	718		30. JWH-145;
607		-
608	719		31. JWH-146;
609		-
610	720		32. JWH-147;
611		-
612	721		33. JWH-148;
613		-
614	722		34. JWH-149;
615		-
616	723		35. JWH-150;
617		-
618		-	ENR. S. B. NO. 452 Page 15
619		-
620	724		36. JWH-156;
621		-
622	725		37. JWH-167;
623		-
624	726		38. JWH-175;
625	727
	728	+	SB452 HFLR Page 15
	729	+	BOLD FACE denotes Committee Amendments. 1
	730	+	2
	731	+	3
	732	+	4
	733	+	5
	734	+	6
	735	+	7
	736	+	8
	737	+	9
	738	+	10
	739	+	11
	740	+	12
	741	+	13
	742	+	14
	743	+	15
	744	+	16
	745	+	17
	746	+	18
	747	+	19
	748	+	20
	749	+	21
	750	+	22
	751	+	23
	752	+	24
	753	+
626	754		39. JWH-180;
627		-
628	755		40. JWH-181;
629		-
630	756		41. JWH-182;
631		-
632	757		42. JWH-184;
633		-
634	758		43. JWH-185;
635		-
636	759		44. JWH-189;
637		-
638	760		45. JWH-192;
639		-
640	761		46. JWH-193;
641		-
642	762		47. JWH-194;
643		-
644	763		48. JWH-195;
645		-
646	764		49. JWH-196;
647		-
648	765		50. JWH-197;
649		-
650	766		51. JWH-198;
651		-
652	767		52. JWH-199;
653		-
654	768		53. JWH-200;
655		-
656	769		54. JWH-201;
657		-
658	770		55. JWH-202;
659		-
660	771		56. JWH-203;
661		-
662		-	ENR. S. B. NO. 452 Page 16
663		-
664	772		57. JWH-204;
665		-
666	773		58. JWH-205;
667		-
668	774		59. JWH-206;
669		-
670	775		60. JWH-207;
671		-
672	776		61. JWH-208;
673		-
674	777		62. JWH-209;
675	778
	779	+	SB452 HFLR Page 16
	780	+	BOLD FACE denotes Committee Amendments. 1
	781	+	2
	782	+	3
	783	+	4
	784	+	5
	785	+	6
	786	+	7
	787	+	8
	788	+	9
	789	+	10
	790	+	11
	791	+	12
	792	+	13
	793	+	14
	794	+	15
	795	+	16
	796	+	17
	797	+	18
	798	+	19
	799	+	20
	800	+	21
	801	+	22
	802	+	23
	803	+	24
	804	+
676	805		63. JWH-210;
677		-
678	806		64. JWH-211;
679		-
680	807		65. JWH-212;
681		-
682	808		66. JWH-213;
683		-
684	809		67. JWH-234;
685		-
686	810		68. JWH-235;
687		-
688	811		69. JWH-236;
689		-
690	812		70. JWH-237;
691		-
692	813		71. JWH-239;
693		-
694	814		72. JWH-240;
695		-
696	815		73. JWH-241;
697		-
698	816		74. JWH-242;
699		-
700	817		75. JWH-243;
701		-
702	818		76. JWH-244;
703		-
704	819		77. JWH-245;
705		-
706		-	ENR. S. B. NO. 452 Page 17
707		-
708	820		78. JWH-246;
709		-
710	821		79. JWH-248;
711		-
712	822		80. JWH-249;
713		-
714	823		81. JWH-250;
715		-
716	824		82. JWH-251;
717		-
718	825		83. JWH-252;
719		-
720	826		84. JWH-253;
721		-
722	827		85. JWH-262;
723		-
724	828		86. JWH-292;
725	829
	830	+	SB452 HFLR Page 17
	831	+	BOLD FACE denotes Committee Amendments. 1
	832	+	2
	833	+	3
	834	+	4
	835	+	5
	836	+	6
	837	+	7
	838	+	8
	839	+	9
	840	+	10
	841	+	11
	842	+	12
	843	+	13
	844	+	14
	845	+	15
	846	+	16
	847	+	17
	848	+	18
	849	+	19
	850	+	20
	851	+	21
	852	+	22
	853	+	23
	854	+	24
	855	+
726	856		87. JWH-293;
727		-
728	857		88. JWH-302;
729		-
730	858		89. JWH-303;
731		-
732	859		90. JWH-304;
733		-
734	860		91. JWH-305;
735		-
736	861		92. JWH-306;
737		-
738	862		93. JWH-307;
739		-
740	863		94. JWH-308;
741		-
742	864		95. JWH-311;
743		-
744	865		96. JWH-312;
745		-
746	866		97. JWH-313;
747		-
748	867		98. JWH-314;
749		-
750		-	ENR. S. B. NO. 452 Page 18
751		-
752	868		99. JWH-315;
753		-
754	869		100. JWH-316;
755		-
756	870		101. JWH-346;
757		-
758	871		102. JWH-348;
759		-
760	872		103. JWH-363;
761		-
762	873		104. JWH-364;
763		-
764	874		105. JWH-365;
765		-
766	875		106. JWH-367;
767		-
768	876		107. JWH-368;
769		-
770	877		108. JWH-369;
771		-
772	878		109. JWH-370;
773		-
774	879		110. JWH-371;
775	880
	881	+	SB452 HFLR Page 18
	882	+	BOLD FACE denotes Committee Amendments. 1
	883	+	2
	884	+	3
	885	+	4
	886	+	5
	887	+	6
	888	+	7
	889	+	8
	890	+	9
	891	+	10
	892	+	11
	893	+	12
	894	+	13
	895	+	14
	896	+	15
	897	+	16
	898	+	17
	899	+	18
	900	+	19
	901	+	20
	902	+	21
	903	+	22
	904	+	23
	905	+	24
	906	+
776	907		111. JWH-373;
777		-
778	908		112. JWH-386;
779		-
780	909		113. JWH-387;
781		-
782	910		114. JWH-392;
783		-
784	911		115. JWH-394;
785		-
786	912		116. JWH-395;
787		-
788	913		117. JWH-397;
789		-
790	914		118. JWH-398;
791		-
792	915		119. JWH-399;
793		-
794		-	ENR. S. B. NO. 452 Page 19
795		-
796	916		120. JWH-400;
797		-
798	917		121. JWH-412;
799		-
800	918		122. JWH-413;
801		-
802	919		123. JWH-414;
803		-
804	920		124. JWH-415;
805		-
806	921		125. CP-55, 940;
807		-
808	922		126. CP-47, 497;
809		-
810	923		127. HU-210;
811		-
812	924		128. HU-211;
813		-
814	925		129. WIN-55, 212-2;
815		-
816	926		130. AM-2201;
817		-
818	927		131. AM-2233;
819		-
820	928		132. JWH-018 adamantyl-carboxamide;
821		-
822	929		133. AKB48;
823		-
824	930		134. JWH-122 N-(4-pentenyl)analog;
825	931
	932	+	SB452 HFLR Page 19
	933	+	BOLD FACE denotes Committee Amendments. 1
	934	+	2
	935	+	3
	936	+	4
	937	+	5
	938	+	6
	939	+	7
	940	+	8
	941	+	9
	942	+	10
	943	+	11
	944	+	12
	945	+	13
	946	+	14
	947	+	15
	948	+	16
	949	+	17
	950	+	18
	951	+	19
	952	+	20
	953	+	21
	954	+	22
	955	+	23
	956	+	24
	957	+
826	958		135. MAM2201;
827		-
828	959		136. URB597;
829		-
830	960		137. URB602;
831		-
832	961		138. URB754;
833		-
834	962		139. UR144;
835		-
836	963		140. XLR11;
837		-
838		-	ENR. S. B. NO. 452 Page 20
839		-
840	964		141. A-796,260;
841		-
842	965		142. STS-135;
843		-
844	966		143. AB-FUBINACA;
845		-
846	967		144. AB-PINACA;
847		-
848	968		145. PB-22;
849		-
850	969		146. AKB48 N-5-Fluorpentyl;
851		-
852	970		147. AM1248;
853		-
854	971		148. FUB-PB-22;
855		-
856	972		149. ADB-FUBINACA;
857		-
858	973		150. BB-22;
859		-
860	974		151. 5-Fluoro PB-22; or
861		-
862	975		152. 5-Fluoro AKB-48.
863		-
864	976		G. In addition to those substances liste d in subsection F of
865	977		this section, unless specifically excepted or unless listed in
866	978		another schedule, any material, compound, mixture, or preparation
867	979		which contains any quantity of a synthetic cannabinoid found to be
868	980		in any of the following chemical groups :
	981	+
	982	+	SB452 HFLR Page 20
	983	+	BOLD FACE denotes Committee Amendments. 1
	984	+	2
	985	+	3
	986	+	4
	987	+	5
	988	+	6
	989	+	7
	990	+	8
	991	+	9
	992	+	10
	993	+	11
	994	+	12
	995	+	13
	996	+	14
	997	+	15
	998	+	16
	999	+	17
	1000	+	18
	1001	+	19
	1002	+	20
	1003	+	21
	1004	+	22
	1005	+	23
	1006	+	24
869	1007
870	1008		1. Naphthoylindoles: any compound containing a 3 -(1-
871	1009		naphthoyl)indole structure with or without substitution at the
872	1010		nitrogen atom of the indole ring by an a lkyl, haloalkyl, cyanoalkyl,
873	1011		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
874	1012		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
875	1013		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
876	1014		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
877	1015		halophenyl group, whether or not further substituted on the indole
878	1016		ring to any extent, and whether or not substituted on the naphthyl
879	1017		ring to any extent. Naphthoylindoles include, but are not limited
880	1018		to:
881		-
882		-	ENR. S. B. NO. 452 Page 21
883		-
884	1019		a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
885	1020		200),
	1021	+	b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
	1022	+	c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
	1023	+	d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
	1024	+	e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
	1025	+	f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
	1026	+	g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
	1027	+	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
	1028	+	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
	1029	+	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
	1030	+	k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
	1031	+	l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
886	1032
887		-	b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
888		-
889		-	c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
890		-
891		-	d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
892		-
893		-	e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
894		-
895		-	f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
896		-
897		-	g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
898		-
899		-	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
900		-
901		-	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
902		-
903		-	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
904		-
905		-	k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
906		-
907		-	l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
	1033	+	SB452 HFLR Page 21
	1034	+	BOLD FACE denotes Committee Amendments. 1
	1035	+	2
	1036	+	3
	1037	+	4
	1038	+	5
	1039	+	6
	1040	+	7
	1041	+	8
	1042	+	9
	1043	+	10
	1044	+	11
	1045	+	12
	1046	+	13
	1047	+	14
	1048	+	15
	1049	+	16
	1050	+	17
	1051	+	18
	1052	+	19
	1053	+	20
	1054	+	21
	1055	+	22
	1056	+	23
	1057	+	24
908	1058
909	1059		m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
910	1060		(JWH-098),
911		-
912	1061		n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
913		-
914	1062		o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
915	1063		naphthoyl)indole (AM-1220),
916		-
917	1064		p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
918	1065		(MAM-2201), or
919		-
920	1066		q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
921		-
922	1067		2. Naphthylmethylindoles: any compound containing a 1H-indol-3-
923	1068		yl-(1-naphthyl)methane structure with or without substitution at the
924	1069		nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
925		-
926		-	ENR. S. B. NO. 452 Page 22
927	1070		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
928	1071		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
929	1072		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
930	1073		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
931	1074		halophenyl group, whether or not further substituted on the indole
932	1075		ring to any extent, and whether or not substituted on the naphthyl
933	1076		ring to any extent. Naphthylmethylindoles include, but are not
934	1077		limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);
935		-
936	1078		3. Naphthoylpyrroles: any compound containing a 3-(1-
937	1079		naphthoyl)pyrrole structure with or without substitution at the
938	1080		nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
939	1081		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
940	1082		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
	1083	+
	1084	+	SB452 HFLR Page 22
	1085	+	BOLD FACE denotes Committee Amendments. 1
	1086	+	2
	1087	+	3
	1088	+	4
	1089	+	5
	1090	+	6
	1091	+	7
	1092	+	8
	1093	+	9
	1094	+	10
	1095	+	11
	1096	+	12
	1097	+	13
	1098	+	14
	1099	+	15
	1100	+	16
	1101	+	17
	1102	+	18
	1103	+	19
	1104	+	20
	1105	+	21
	1106	+	22
	1107	+	23
	1108	+	24
	1109	+
941	1110		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
942	1111		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
943	1112		phenyl, or halophenyl group, whether or not further substituted on
944	1113		the pyrrole ring to any extent, and whether or not substituted on
945	1114		the naphthyl group to an y extent. Naphthoylpyrroles include, but
946	1115		are not limited to:
947		-
948	1116		a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
949		-
950	1117		b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
951	1118		(JWH-370),
952		-
953	1119		c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
954		-
955	1120		d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);
956		-
957	1121		4. Naphthylideneindenes: any compound containing a 1-(1-
958	1122		naphthylmethylene)indene structure with or without substitution at
959	1123		the 3-position of the indene ring by a n alkyl, haloalkyl,
960	1124		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl,
961	1125		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
962	1126		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
963	1127		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
964	1128		phenyl, or halophenyl group, whether or not further substituted on
965	1129		the indene group to any extent, and whether or not substituted on
966	1130		the naphthyl group to any extent. Naphthylmethylindenes include,
967	1131		but are not limited to, (1-[(3-pentyl)-1H-inden-1-
968	1132		ylidene)methyl]naphthalene (JWH-176);
969	1133
970		-	ENR. S. B. NO. 452 Page 23
	1134	+	SB452 HFLR Page 23
	1135	+	BOLD FACE denotes Committee Amendments. 1
	1136	+	2
	1137	+	3
	1138	+	4
	1139	+	5
	1140	+	6
	1141	+	7
	1142	+	8
	1143	+	9
	1144	+	10
	1145	+	11
	1146	+	12
	1147	+	13
	1148	+	14
	1149	+	15
	1150	+	16
	1151	+	17
	1152	+	18
	1153	+	19
	1154	+	20
	1155	+	21
	1156	+	22
	1157	+	23
	1158	+	24
971	1159
972	1160		5. Phenylacetylindoles: any compound containing a 3-
973	1161		phenylacetylindole structure with or without substitution a t the
974	1162		nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
975	1163		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
976	1164		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
977	1165		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
978	1166		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
979	1167		halophenyl group, whether or no t further substituted on the indole
980	1168		ring to any extent, and whethe r or not substituted on the phenyl
981	1169		ring to any extent. Phenylacetylindoles include, but are not
982	1170		limited to:
983		-
984	1171		a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
985		-
986	1172		b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
987	1173		(RCS-8),
988		-
989	1174		c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
990		-
991	1175		d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
992		-
993	1176		e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
994		-
995	1177		f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
996		-
997	1178		6. Cyclohexylphenols: any compound containing a 2 -(3-
998	1179		hydroxycyclohexyl)phenol struc ture with or without subs titution at
999	1180		the 5-position of the phenolic r ing by an alkyl, haloalkyl,
1000	1181		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1001	1182		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1002	1183		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
	1184	+
	1185	+	SB452 HFLR Page 24
	1186	+	BOLD FACE denotes Committee Amendments. 1
	1187	+	2
	1188	+	3
	1189	+	4
	1190	+	5
	1191	+	6
	1192	+	7
	1193	+	8
	1194	+	9
	1195	+	10
	1196	+	11
	1197	+	12
	1198	+	13
	1199	+	14
	1200	+	15
	1201	+	16
	1202	+	17
	1203	+	18
	1204	+	19
	1205	+	20
	1206	+	21
	1207	+	22
	1208	+	23
	1209	+	24
	1210	+
1003	1211		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
1004	1212		phenyl, or halophenyl group, and whether or not further substituted
1005	1213		on the cyclohexyl ring to any extent. Cyclohexylphenols include,
1006	1214		but are not limited to:
1007		-
1008	1215		a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
1009	1216		hydroxycyclohexyl]-phenol (CP-47,497),
1010		-
1011		-
1012		-	ENR. S. B. NO. 452 Page 24
1013	1217		b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
1014	1218		phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
1015	1219		or
1016		-
1017	1220		c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
1018	1221		hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
1019		-
1020	1222		7. Benzoylindoles: any compound conta ining a 3-(benzoyl)indole
1021	1223		structure with or without substitution at the nitrogen atom of the
1022	1224		indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1023	1225		cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
1024	1226		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1025	1227		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1026	1228		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1027	1229		halophenyl group, whether o r not further substituted on the indole
1028	1230		ring to any extent, and whether or not substituted on the phenyl
1029	1231		group to any extent. Benzoylindoles include, but are not limited
1030	1232		to:
	1233	+	a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
1031	1234
1032		-	a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
	1235	+	SB452 HFLR Page 25
	1236	+	BOLD FACE denotes Committee Amendments. 1
	1237	+	2
	1238	+	3
	1239	+	4
	1240	+	5
	1241	+	6
	1242	+	7
	1243	+	8
	1244	+	9
	1245	+	10
	1246	+	11
	1247	+	12
	1248	+	13
	1249	+	14
	1250	+	15
	1251	+	16
	1252	+	17
	1253	+	18
	1254	+	19
	1255	+	20
	1256	+	21
	1257	+	22
	1258	+	23
	1259	+	24
1033	1260
1034	1261		b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
1035	1262		methoxybenzoyl)indole (Pravadoline or W IN 48, 098),
1036		-
1037	1263		c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
1038		-
1039	1264		d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
1040		-
1041	1265		e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
1042	1266		iodobenzoyl)indole (AM-2233);
1043		-
1044	1267		8. Cyclopropoylindoles: Any compound containing a 3-
1045	1268		(cyclopropoyl)indole structure with substitutio n at the nitrogen
1046	1269		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1047	1270		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
1048	1271		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1049	1272		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1050	1273		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1051	1274		halophenyl group, whether or not further substituted in the indole
1052	1275		ring to any extent and whether or not substituted in t he
1053	1276		cyclopropoyl ring to a ny extent. Cyclopropoylindoles inclu de, but
1054	1277		are not limited to:
1055		-
1056		-	ENR. S. B. NO. 452 Page 25
1057		-
1058	1278		a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
1059	1279		(UR-144),
1060		-
1061	1280		b. 1-(5-chloropentyl)-3-(2,2,3,3-
1062	1281		tetramethylcyclopropoyl)indole (5Cl -UR-144), or
1063		-
1064	1282		c. 1-(5-fluoropentyl)-3-(2,2,3,3-
1065	1283		tetramethylcyclopropoyl)indole (XLR11);
	1284	+
	1285	+	SB452 HFLR Page 26
	1286	+	BOLD FACE denotes Committee Amendments. 1
	1287	+	2
	1288	+	3
	1289	+	4
	1290	+	5
	1291	+	6
	1292	+	7
	1293	+	8
	1294	+	9
	1295	+	10
	1296	+	11
	1297	+	12
	1298	+	13
	1299	+	14
	1300	+	15
	1301	+	16
	1302	+	17
	1303	+	18
	1304	+	19
	1305	+	20
	1306	+	21
	1307	+	22
	1308	+	23
	1309	+	24
1066	1310
1067	1311		9. Indole Amides: Any compound containing a 1H-Indole-3-
1068	1312		carboxamide structure with or without substitution at the nitrogen
1069	1313		atom of the indole ring by an alkyl, haloalk yl, cyanoalkyl, alkenyl,
1070	1314		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
1071	1315		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1072	1316		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1073	1317		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1074	1318		halophenyl group, whethe r or not substituted at t he carboxamide
1075	1319		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1076	1320		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1077	1321		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1078	1322		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1079	1323		further substituted in the indole, adamantyl, naphthyl, phenyl,
1080	1324		pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
1081	1325		Amides include, but are not limited to:
1082		-
1083	1326		a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
1084	1327		(2NE1),
1085		-
1086	1328		b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
1087	1329		carboxamide (STS-135),
1088		-
1089	1330		c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
1090	1331		indole-3-carboxamide (ADBICA),
1091		-
1092	1332		d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
1093	1333		fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
1094	1334
	1335	+	SB452 HFLR Page 27
	1336	+	BOLD FACE denotes Committee Amendments. 1
	1337	+	2
	1338	+	3
	1339	+	4
	1340	+	5
	1341	+	6
	1342	+	7
	1343	+	8
	1344	+	9
	1345	+	10
	1346	+	11
	1347	+	12
	1348	+	13
	1349	+	14
	1350	+	15
	1351	+	16
	1352	+	17
	1353	+	18
	1354	+	19
	1355	+	20
	1356	+	21
	1357	+	22
	1358	+	23
	1359	+	24
	1360	+
1095	1361		e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
1096	1362		(NNE1),
1097		-
1098		-
1099		-	ENR. S. B. NO. 452 Page 26
1100	1363		f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
1101	1364		carboxamide (5F-NNE1),
1102		-
1103	1365		g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
1104	1366		or
1105		-
1106	1367		h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
1107	1368		(5F-SDB-006);
1108		-
1109	1369		10. Indole Esters: Any compound containing a 1H-Indole-3-
1110	1370		carboxylate structure with or without substitution at the nitrogen
1111	1371		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1112	1372		cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1-(N-methyl-
1113	1373		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1114	1374		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1115	1375		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1116	1376		halophenyl group, whet her or not substituted at the carboxylate
1117	1377		group by an adamantyl, naphthyl, phenyl, benzyl, q uinolinyl,
1118	1378		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1119	1379		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1120	1380		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1121	1381		further substituted in the indole, adamantyl, nap hthyl, phenyl,
1122	1382		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
1123	1383		Esters include, but are not limited to:
1124	1384
	1385	+	SB452 HFLR Page 28
	1386	+	BOLD FACE denotes Committee Amendments. 1
	1387	+	2
	1388	+	3
	1389	+	4
	1390	+	5
	1391	+	6
	1392	+	7
	1393	+	8
	1394	+	9
	1395	+	10
	1396	+	11
	1397	+	12
	1398	+	13
	1399	+	14
	1400	+	15
	1401	+	16
	1402	+	17
	1403	+	18
	1404	+	19
	1405	+	20
	1406	+	21
	1407	+	22
	1408	+	23
	1409	+	24
	1410	+
1125	1411		a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
1126	1412		22),
1127		-
1128	1413		b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
1129	1414		carboxylate (5F-PB-22),
1130		-
1131	1415		c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
1132	1416		carboxylate (BB-22),
1133		-
1134	1417		d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
1135	1418		carboxylate (FDU-PB-22), or
1136		-
1137	1419		e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
1138	1420		carboxylate (NM2201);
1139		-
1140	1421		11. Adamantanoylindoles: Any compound containing an
1141	1422		adamantanyl-(1H-indol-3-yl)methanone structure with or without
1142		-
1143		-	ENR. S. B. NO. 452 Page 27
1144	1423		substitution at the ni trogen atom of the indole ring by an alkyl,
1145	1424		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmet hyl, cycloalkylethyl,
1146	1425		benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1147	1426		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
1148	1427		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1149	1428		phenyl, or halophenyl group, whether o r not further substituted in
1150	1429		the indole ring to any extent and whethe r or not substituted in the
1151	1430		adamantyl ring to any extent. Adamantanoylindoles include, but are
1152	1431		not limited to:
1153		-
1154	1432		a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
1155	1433		indol-3-yl]methanone (AM1248), or
1156	1434
	1435	+	SB452 HFLR Page 29
	1436	+	BOLD FACE denotes Committee Amendments. 1
	1437	+	2
	1438	+	3
	1439	+	4
	1440	+	5
	1441	+	6
	1442	+	7
	1443	+	8
	1444	+	9
	1445	+	10
	1446	+	11
	1447	+	12
	1448	+	13
	1449	+	14
	1450	+	15
	1451	+	16
	1452	+	17
	1453	+	18
	1454	+	19
	1455	+	20
	1456	+	21
	1457	+	22
	1458	+	23
	1459	+	24
	1460	+
1157	1461		b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
1158	1462		001);
1159		-
1160	1463		12. Carbazole Ketone: Any compound containing (9H-carbazole-3-
1161	1464		yl) methanone structure wi th or without substitution at the nitrogen
1162	1465		atom of the carbazole r ing by an alkyl, haloal kyl, cyanoalkyl,
1163	1466		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
1164	1467		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
1165	1468		2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1166	1469		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1167	1470		halophenyl group, with substitution at the carbon of the m ethanone
1168	1471		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1169	1472		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1170	1473		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1171	1474		dimethyl-1-oxobutan-2-yl or pyrrole group, and wheth er or not
1172	1475		further substituted at the carbazole, adamantyl, naphthyl, phenyl,
1173	1476		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
1174	1477		Ketones include, but are not limited to, na phthalen-1-yl(9-pentyl-
1175	1478		9H-carbazol-3-yl)methanone (EG-018);
1176		-
1177	1479		13. Benzimidazole Ketone: Any compound containing
1178	1480		(benzimidazole-2-yl) methanone structure with or withou t
1179	1481		substitution at either nitrogen atom of the benzimidazole ring b y an
1180	1482		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
1181	1483		cycloalkylethyl, benzyl, halob enzyl, 1-(N-methyl-2-
1182	1484		piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
	1485	+
	1486	+	SB452 HFLR Page 30
	1487	+	BOLD FACE denotes Committee Amendments. 1
	1488	+	2
	1489	+	3
	1490	+	4
	1491	+	5
	1492	+	6
	1493	+	7
	1494	+	8
	1495	+	9
	1496	+	10
	1497	+	11
	1498	+	12
	1499	+	13
	1500	+	14
	1501	+	15
	1502	+	16
	1503	+	17
	1504	+	18
	1505	+	19
	1506	+	20
	1507	+	21
	1508	+	22
	1509	+	23
	1510	+	24
	1511	+
1183	1512		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1184	1513		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or
1185	1514		halophenyl group, with substitution at the carbon of the methan one
1186		-
1187		-	ENR. S. B. NO. 452 Page 28
1188	1515		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1189	1516		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1190	1517		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1191	1518		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1192	1519		further substituted in the benzimidazole, adamantyl, naphthyl,
1193	1520		phenyl, pyrrole, quinolinyl, o r cycloalkyl rings to any extent.
1194	1521		Benzimidazole Ketones include, but are not limited to:
1195		-
1196	1522		a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
1197	1523		l)methanone (JWH-018 benzimidazole analog), or
1198		-
1199	1524		b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
1200	1525		yl)(naphthalen-1-yl)methanone (FUBIMINA); and
1201		-
1202	1526		14. Modified by Replacement: any compound defined in this
1203	1527		subsection that is modified by r eplacement of a carbon with nitrogen
1204	1528		in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
1205		-
1206	1529		H. Any prescription drug approved by the federal Food and Drug
1207	1530		Administration under the pr ovisions of Section 505 of the Federal
1208	1531		Food, Drug and Cosmeti c Act, Title 21 of the United States Code,
1209	1532		Section 355, that is designated, rescheduled or deleted as a
1210	1533		controlled substance under federal law by the United States Drug
1211	1534		Enforcement Administration shall be exc luded from Schedule I a nd
1212	1535		shall be prescribed, d istributed, dispensed or used in accordance
	1536	+
	1537	+	SB452 HFLR Page 31
	1538	+	BOLD FACE denotes Committee Amendments. 1
	1539	+	2
	1540	+	3
	1541	+	4
	1542	+	5
	1543	+	6
	1544	+	7
	1545	+	8
	1546	+	9
	1547	+	10
	1548	+	11
	1549	+	12
	1550	+	13
	1551	+	14
	1552	+	15
	1553	+	16
	1554	+	17
	1555	+	18
	1556	+	19
	1557	+	20
	1558	+	21
	1559	+	22
	1560	+	23
	1561	+	24
	1562	+
1213	1563		with federal law upon the issuance of a notice, final rule or
1214	1564		interim final rule by the United Sta tes Drug Enforcement
1215	1565		Administration designating, rescheduling or deleting as a controlled
1216	1566		substance such a drug pr oduct under federal law, unless and until
1217	1567		the Board of Pharmacy takes action pursuant to Section 2-201 of this
1218	1568		title. If the Board of Pharmac y does not take action pursuant to
1219	1569		Section 2-201 of this title, the drug product shall be deemed to be
1220	1570		designated, rescheduled or deleted as a controlled subs tance in
1221	1571		accordance with federal law and in compliance with the Uniform
1222	1572		Controlled Dangerous Subst ances Act.
1223		-
1224	1573		SECTION 2. This act shall become effective November 1, 2023.
1225	1574
1226		-
1227		-	ENR. S. B. NO. 452 Page 29
1228		-	Passed the Senate the 2nd day of March, 2023.
1229		-
1230		-
1231		-
1232		-	Presiding Officer of the Senate
1233		-
1234		-
1235		-	Passed the House of Representatives the 20th day of April, 2023.
1236		-
1237		-
1238		-
1239		-	Presiding Officer of the House
1240		-	of Representatives
1241		-
1242		-	OFFICE OF THE GOVERNOR
1243		-	Received by the Office of the Governor this _______ _____________
1244		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1245		-	By: _______________________________ __
1246		-	Approved by the Governor of the State of Oklahoma this _____ ____
1247		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1248		-
1249		-	_________________________________
1250		-	Governor of the State of Oklahoma
1251		-
1252		-
1253		-	OFFICE OF THE SECRETARY OF STATE
1254		-	Received by the Office of the Secretary of State this _______ ___
1255		-	day of __________________, 20 _______, at _______ o'clock _______ M.
1256		-	By: _______________________________ __
	1575	+	COMMITTEE REPORT BY: COMMITTEE ON ALC OHOL, TOBACCO AND CONTROLLED
	1576	+	SUBSTANCES, dated 04/12/2023 - DO PASS.